Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
BioCentury
|
Jan 10, 2013
Distillery Therapeutics
Indication: Cardiovascular disease
...modulating necrosis via SIRT2 inhibition could have benefit in other indications, such as neurodegenerative diseases.
Indus Biotech Pte. Ltd.
's...
Read More
BioCentury
|
Sep 20, 2012
Distillery Therapeutics
Indication: Neurology
...of Sirt2 deletion in other mouse models of PD and developing selective, brain-penetrant SIRT2 inhibitors.
Indus Biotech Pte. Ltd.
...
Read More
BioCentury
|
Jun 28, 2012
Distillery Therapeutics
Indication: Neurology
...a previously reported reference compound. Next steps include evaluating the lead compounds in animal models.
Indus Biotech Pte. Ltd.
...
Read More
Items per page:
10
1 - 3 of 3
BioCentury
|
Jan 10, 2013
Distillery Therapeutics
Indication: Cardiovascular disease
...modulating necrosis via SIRT2 inhibition could have benefit in other indications, such as neurodegenerative diseases.
Indus Biotech Pte. Ltd.
's...
Read More
BioCentury
|
Sep 20, 2012
Distillery Therapeutics
Indication: Neurology
...of Sirt2 deletion in other mouse models of PD and developing selective, brain-penetrant SIRT2 inhibitors.
Indus Biotech Pte. Ltd.
...
Read More
BioCentury
|
Jun 28, 2012
Distillery Therapeutics
Indication: Neurology
...a previously reported reference compound. Next steps include evaluating the lead compounds in animal models.
Indus Biotech Pte. Ltd.
...
Read More
Items per page:
10
1 - 3 of 3
Previous page
Next page